Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P16473: Variant p.Pro449Leu

Thyrotropin receptor
Gene: TSHR
Feedback?
Variant information Variant position: help 449 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Proline (P) to Leucine (L) at position 449 (P449L, p.Pro449Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CHNG1; no effect on cell membrane location; upon TSH stimulation decreases more phospholipase C-activating G-protein coupled receptor signaling pathway than adenylate cyclase-activating G-protein coupled receptor signaling pathway. Any additional useful information about the variant.


Sequence information Variant position: help 449 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 764 The length of the canonical sequence.
Location on the sequence: help LLGNVFVLLILLTSHYKLNV P RFLMCNLAFADFCMGMYLLL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         LLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLL

                              LLGNVFVLIVLLTSHYKLTVPRFLMCNLAFADFCMGMYLLL

Mouse                         LLGNIFVLLILLTSHYKLTVPRFLMCNLAFADFCMGVYLLL

Rat                           LLGNVFVLFVLLTSHYKLTVPRFLMCNLAFADFCMGVYLLL

Pig                           LLGNVFVLVILLTSHYKLTVPRFLMCNLAFADFCMGMYLLL

Bovine                        LLGNVFVLVILLTSHYKLTVPRFLMCNLAFADFCMGLYLLL

Sheep                         LLGNVFVLVILLTSHYKLTVPRFLMCNLAFADFCMGLYLLL

Cat                           LLGNVFVLIILLTSHYKLTVPRFLMCNLAFADFCMGMYLLL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 21 – 764 Thyrotropin receptor
Topological domain 442 – 450 Cytoplasmic
Alternative sequence 254 – 764 Missing. In isoform Short.
Alternative sequence 275 – 764 Missing. In isoform 3.
Helix 448 – 477



Literature citations
Loss-of-function variants in a Hungarian cohort reveal structural insights on TSH receptor maturation and signaling.
Labadi A.; Grassi E.S.; Gellen B.; Kleinau G.; Biebermann H.; Ruzsa B.; Gelmini G.; Rideg O.; Miseta A.; Kovacs G.L.; Patocs A.; Felszeghy E.; Nagy E.V.; Mezosi E.; Persani L.;
J. Clin. Endocrinol. Metab. 100:E1039-E1045(2015)
Cited for: VARIANTS CHNG1 ALA-162; ASP-432 AND LEU-449; CHARACTERIZATION OF VARIANTS CHNG1 ASP-432 AND LEU-449;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.